Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.38 |
| ▸ | MTOR | P42345 | 7/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706176 | 0.84 | PIK3CA (0.42) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL17768116 | 0.82 | PIK3CA (0.40) | PIK3CAMTORSYKAKT1SMO | |
| SCHEMBL16754397 | 0.82 | PIK3CA (0.40) | PIK3CAMTORSYKAKT1SMO | |
| SCHEMBL19670402 | 0.80 | PIK3CA (0.37) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL16754693 | 0.78 | PIK3CA (0.41) | PIK3CAMTORAKT1SMOGABRA1 | |
| SCHEMBL19670384 | 0.78 | PIK3CA (0.36) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL16754470 | 0.77 | GABRA1 (0.41) | PIK3CAMTORAKT1GABRA1 | |
| SCHEMBL19670633 | 0.75 | WNT3A (0.34) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL17770593 | 0.72 | PIK3CA (0.41) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL16754549 | 0.72 | PIK3CA (0.41) | PIK3CAMTORPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885SYK 2995/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885SYK 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.